The European Severe Asthma Survey

A patient perspective on severe asthma

Factsheet

In 2005, the European Federation of Allergy and Airway Disease Patients’ Associations (EFA) conducted a survey of 1,300 people with severe asthma in France, Spain, Germany, Sweden and the UK.

In February 2007, EFA’s ‘Limitations in Severe Asthma – results of a European Survey’ was published in the renowned international peer-reviewed publication, Allergy. This further demonstrates the importance of the survey findings and provides an invaluable opportunity to continue to raise awareness of the impact of severe asthma and of the urgent need for higher standards of treatment, care and environmental regulation.

Highlights

The results from this shared European initiative are intended to raise awareness of severe asthma and its impact on patients in Europe.

“It is not just breathlessness, it is extremely painful … the sensation of being squashed, unable to speak, to do anything”

- Around 1.5 million people in Europe live in fear of dying from an attack
- One person in Western Europe dies every hour as a result of asthma¹
- Around 30 million people in Europe have asthma, and as many as 6 million suffer symptoms which are characterised as severe: that is
  - having a wheezing attack and/or sleep disturbance once a week or more often in the last year
  - one or more speech-limiting attacks in the last year
- The total cost of asthma in Europe is €17.7bn per year, and productivity lost to poor asthma control is estimated at €9.8bn per annum²

The human cost

“When I get an infection or the flu it often affects my bronchi, and I cough so violently I could crack a rib”

- Severe asthma has a substantial impact on the quality of life of patients. Attacks can be unpredictable, with symptoms that include “coughing,” “panic attacks,” “gasiing for air,” “sweating,” “wheezing”. “Put a straw in your mouth and breathe through it,” suggests one respondent, “that’s asthma.”
- More than half the respondents say they suffer anxiety and stress because of their asthma, and one in four say that they feel their condition is “life-threatening”. The most common words used to describe asthma were “breathlessness,” “suffocation” and “fear”.
- More than one in three say their social life is restricted: almost a third say asthma stops them going on holiday; 38% say it stops them going out with friends; nearly half (49%) that they can’t have pets or visit people with pets; and 70% are no longer able to participate in physical activities.
“I can’t do activities like swimming or going to the gym. I used to like dancing a lot, but these all became too difficult”

Trigger factors

- Asthma attacks can be triggered by many environmental factors, the most common of which are air pollution, dust, pollen and cigarette smoke. Almost two-fifths of respondents say they are exposed to secondary smoke (56% in Spain).

“When I worked in day care I had colleagues who smoked and who didn’t want to open a window to clear the air because they thought it was too cold”

Social impact

A number mentioned that they felt asthma is a condition “ignored by society.” This is because:

- There is a general lack of understanding about the condition and its potential seriousness
- People with asthma are blamed, often incorrectly, for being smokers (and therefore responsible for their illness)
- Other illnesses such as diabetes have a higher profile (France)
- Environmental factors, such as pollution or smoking in public places, are only being very slowly addressed, if at all.

Current expectations

- The Global Initiative on Asthma (GINA) has issued guidelines setting out the standard of treatment achievable for 90% of patients, if the right medicines are used in the right way at the right time.
- Around one in four fail to meet guidelines for emergency visits, and over half experience restrictions in their daily activities.

What patients want

- Although asthma is a serious condition, EFA says 90% of the deaths could be prevented through increased public awareness, improved access to appropriate healthcare, changes in environmental and healthcare policy, and the development and availability of new more effective treatments.
- Many respondents are optimistic that new more effective drugs will be available in future (71%)
- One in three, 29%, say investing in research is the single most useful thing their government could do to improve their asthma. Others (16%) want a ban on smoking in public places and one in ten want immediate access to specialists when necessary.

Conclusion

The EFA severe asthma survey bears testimony to the impact that severe asthma symptoms place on those who suffer, their families, healthcare providers and society. EFA calls for improved EU policies and higher prioritisation of asthma by national governments around Europe to reduce this burden.

— Ends —
Notes to Editor:

EFA’s severe asthma survey, ‘The limitations of severe asthma: the results of a European survey’, was published in the journal, Allergy, in February 2007.

http://www.blackwellpublishing.com/journal.asp?ref=0105-4538

Survey Methodology

Severe asthma patients were recruited if they met one or more of following criteria:

- Sleep disturbance once a week or more often in the last year
- A wheezing attack once a week or more often in the last year
- One or more speech-limiting attacks in the last year

In the UK, France and Sweden patients were recruited using random digit dialling, whereas in Germany patients were recruited by the field interviewers selecting patients randomly. In Spain patients were recruited through both doctors and field interviewers, who selected patients randomly.

About EFA

The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is a Brussels-based alliance of 32 patient organisations in 19 countries, and one of its overall aims is “to improve the quality of life of people with asthma, chronic obstructive pulmonary disease and allergy, and of their carers throughout Europe”.

EFA wishes to express their ongoing thanks to Asthma UK who carried out the research and for the participation and support of Deutcher Allergie- und Asthmabund (DAAB), Germany, Astma- och Allergiförbundet, Sweden, Association Asthme & Allergies, France, and Asociación Asmáticos Madrileños ASMA, Spain.

We would also like to thank the Allergy editorial board and the study authors, Martin Dockrell, Professor Martyn Partridge and Dr Erkka Valovirta.

Finally, EFA wishes to thank Novartis, who supported the survey through an educational grant.

EFA, Central Office, 35 Rue du Congrès, 1000 Brussels, Belgium, www.efanet.org

---

1 World Health Report 2003, Shaping the Future, World Health Organisation
2 European Respiratory Society. The European White Lung Book: The First Comprehensive Survey in Respiratory Health in Europe 2003
www.ginasthma.com/GuidelineList.asp?l1=2&l2=1